These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25465913)

  • 1. Folinic acid after MTX as prophylaxis for GVHD in pediatric bone marrow transplantation.
    Kodama Y; Fukano R; Noguchi M; Okamura J; Inagaki J
    Int J Hematol; 2015 Jan; 101(1):92-8. PubMed ID: 25465913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT.
    Hudspeth MP; Heath TS; Chiuzan C; Garrett-Mayer E; Nista E; Burton L; Ragucci D
    Bone Marrow Transplant; 2013 Jan; 48(1):46-9. PubMed ID: 22609886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation.
    Nevill TJ; Tirgan MH; Deeg HJ; Klingemann HG; Reece DE; Shepherd JD; Barnett MJ; Phillips GL
    Bone Marrow Transplant; 1992 May; 9(5):349-54. PubMed ID: 1617319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of folinic acid in preventing oral mucositis in allogeneic hematopoietic stem cell transplant patients receiving MTX as prophylaxis for GVHD.
    Sugita J; Matsushita T; Kashiwazaki H; Kosugi M; Takahashi S; Wakasa K; Shiratori S; Ibata M; Shono Y; Shigematsu A; Obara M; Fujimoto K; Endo T; Nishio M; Kondo T; Hashino S; Tanaka J; Asaka M; Imamura M
    Bone Marrow Transplant; 2012 Feb; 47(2):258-64. PubMed ID: 21423118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation.
    Torres A; Martinez F; Gomez P; Herrera C; Rojas R; Gomez-Villagran JL; Garcia-Castellano JM; Velasco F; Andres P; Fornes G
    Blut; 1989 Feb; 58(2):63-8. PubMed ID: 2645954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
    Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
    Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prophylaxis with FK-506 for graft-versus-host disease after transplantation of bone marrow from unrelated donors].
    Hamazaki T; Yagi K; Inoue M; Sakata N; Okamura T; Yasui M; Sasabe M; Kishimoto T; Inoue A; Kawa K
    Rinsho Ketsueki; 2000 May; 41(5):430-6. PubMed ID: 10879106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease.
    Kumar S; Wolf RC; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2002 Aug; 30(3):161-5. PubMed ID: 12189534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of folinic acid in methotrexate-based prophylaxis of graft-versus-host disease following hematopoietic stem cell transplantation.
    AlJohani NI
    Hematology; 2021 Dec; 26(1):620-627. PubMed ID: 34411497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major.
    Ghavamzadeh A; Iravani M; Ashouri A; Mousavi SA; Mahdavi N; Shamshiri A; Hadjibabaie M; Namdar R; Nedaeifard L; Ghaffari H; Alimoghaddam K
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):301-8. PubMed ID: 18275896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation.
    Iguchi A; Terashita Y; Sugiyama M; Ohshima J; Sato TZ; Cho Y; Kobayashi R; Ariga T
    Pediatr Transplant; 2016 Feb; 20(1):114-9. PubMed ID: 26526424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
    Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
    Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporin A and mini short-term methotrexate vs cyclosporin A as graft-versus-host disease prophylaxis in patients with beta thalassemia major undergoing allogeneic blood and marrow transplantation.
    Iravani M; Mousavi A; Gholibeikian S; Bahar B; Samiee S; Ashouri A; Eghbal L; Ghavamzadeh A
    Bone Marrow Transplant; 2005 Jun; 35(11):1095-9. PubMed ID: 15821773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of stem cell source on allogeneic stem cell transplantation outcome in hematological malignancies.
    Stamatović D; Balint B; Tukić L; Elez M; Tarabar O; Todorović M; Ostojić G; Tatomirovic Z; Ljubenov M; Marjanović S; Malesević M
    Vojnosanit Pregl; 2011 Dec; 68(12):1026-32. PubMed ID: 22352263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing the haematological recovery after allogeneic bone marrow transplantation in leukaemia patients treated with methotrexate-containing GVHD prophylaxis: a single-centre experience.
    Hassan HT; Krog C; Stockschläder M; Schleimer B; Zeller W; Krüger W; Erttmann R; Zander AR
    Anticancer Res; 1997; 17(1B):589-99. PubMed ID: 9066585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.